Similarly, loss of function due to germline or somatic deletions in tumour suppressor genes may confer drug sensitivity, such as that of high grade serous ovarian cancer with BRCA1 or BRCA2 mutations, to the PARP inhibitor olaparib [4]. Here, BRCA2 is linked to neoplasm.